

CURRICULUM VITAE

(one page summary)



Name: **Rayasam (Ray) S .Prasad**

Address: 20881 Canyon View Drive, Saratoga,
CA 95070 USA

India Plot No: 624, Road No: 35, Jubilee Hills,
Hyderabad 500 033, India (Corresponding)

Telephone: +1 408-872-0232 (US)
+91 8418 304211 (business)
+91 9701110088 (mobile)

Fax: +91 8418 304159 (business)

Email: prasad.ray@biologicale.co.in (business)
Rayasam2@aol.com (home)

Citizenship: USA

Senior management executive with twenty-five years technical management experience with emphasis on worldwide Regulatory Affairs, Compliance, Quality Assurance, Quality Control, Process Validation & Project Management in Bio-Pharmaceuticals and Vaccines

PROFESSIONAL HISTORY

2008-Current Chief Operating Officer – Global (Biologics), **Biological E. Limited**, India

2007-2008 Senior Vice President– Global Quality Management & Regulatory Compliance, **Reliance Life Sciences**, India

2004-2007 Senior Vice President – Regulatory Affairs, Compliance & QA, **Titan Pharmaceuticals Inc.**, South San Francisco, CA 94080

2002-2004 Senior Vice President – World Wide Regulatory Affairs & Compliance, **Genzyme Corporation** formerly **Sangstat Medical Corporation**, Fremont CA 94555

1999-2002 Senior Vice President – Technical Affairs, **Medimmune Vaccines** formerly **Aviron, Mountain View**, CA 94040

1994-1999 Head (Vice President) of Regulatory, Quality & Drug Safety– **Chiron Corporation, Emeryville, CA,USA & Chiron SpA, Italy and Chiron Behring, Germany**

1986-1994 Senior Manager – QA – **Genentech Inc**, South San Francisco, CA 94080

1981-1986 Project Head - **Borroughs Wellcome Co**, Greenville, North Carolina

1977-1981 US Navy

EDUCATION

B.S. in Pharmacy, Andhra University, India
Graduate Courses in Pharmaceutical Sciences, Philadelphia
College of Pharmacy and Sciences, USA

:

Overview of Global Vaccines- Key trends, Issues and future

Several promising new vaccines have just been licensed or are at advanced stages of development in US/Europe as well as in India and the developing world in general. Among these are vaccines for H- Influenzae type B, rotavirus for diarrhoea, pneumococcal disease, which together claim over a million people each year, most of them in developing countries. Progress is also being made on vaccines for diseases of regional importance such as Japanese Encephalitis and meningococcal meningitis type A which causes frequent epidemics and high rates of death and disability in some Asian/African countries.

Challenges to vaccine development and future:

1. Access to technology (HPV, new vaccines)
2. IP
3. Predictability in markets (regional issues of political will and affordability combined with lack of sufficient data on incidence and surveillance = no financial incentive)
4. Cost of development (discovery, process engineering, toxicology and animal studies to human Phase I, II, and III trials.)
5. View is similar to new products even for existing products (no equivalence possible)
6. Dedicated & specialized infrastructure(very capital intensive)

Global alliances and modern technologies become extremely important to achieve the goal which remains to "Develop vaccines of major public health importance and strive to make available these available to people who need them the most".